Islet Sciences Receives Japanese Patent Covering New Medications for Diabetes

Islet Sciences Receives Japanese Patent Covering New Medications for Diabetes

NEW YORK--(BUSINESS WIRE)-- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Japanese Patent for allowed claims, Patent Application No. 2008-529208.

"This patent is another aspect to the value of our therapies which represents such a large market opportunity for the Diabetic community and our stakeholders," said John Steel, Chairman and CEO of Islet Sciences. "We are pleased to announce this significant milestone which clearly strengthens our global value proposition. This patent provides further evidence for the value and promise of this technology to be developed for treatments for diabetes and related complications."


The notice of allowed claims includes the use and composition for small molecules for prevention or treatment of a pathological inflammatory or autoimmune condition. In particular the pathological conditions include Type 1 diabetes, atherosclerosis, type 2 diabetes, disorders associated with visceral obesity, multiple sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and Alzheimer's disease.

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes.  The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti inflammatory compounds. For more information: www.isletsciences.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.



Islet Sciences Investor:
ProActive Capital Group
Jeff Ramson, 646-863-6893
jramson@proactivecapital.com

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:

The article Islet Sciences Receives Japanese Patent Covering New Medications for Diabetes originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

What Is Your Risk Tolerance?

Answer the question "What type of investor am I?".

View Course »

Finding Stock Ideas

Learn to do your research and find investments.

View Course »

Add a Comment

*0 / 3000 Character Maximum